Medirom Healthcare Net Income Over Time
| MRM Stock | USD 1.36 0.03 2.26% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Medirom Healthcare Performance and Medirom Healthcare Correlation. Will Health Care Providers & Services sector continue expanding? Could Medirom diversify its offerings? Factors like these will boost the valuation of Medirom Healthcare. Expected growth trajectory for Medirom significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Medirom Healthcare data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 0.278 | Earnings Share 0.39 | Revenue Per Share | Quarterly Revenue Growth (0.07) | Return On Assets |
Understanding Medirom Healthcare requires distinguishing between market price and book value, where the latter reflects Medirom's accounting equity. The concept of intrinsic value - what Medirom Healthcare's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Medirom Healthcare's price substantially above or below its fundamental value.
Understanding that Medirom Healthcare's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Medirom Healthcare represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Medirom Healthcare's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Net Income Analysis
Compare Medirom Healthcare and related stocks such as Park Ha Biological, Sonder Holdings, and YY Group Holding Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BYAH | (485 K) | (485 K) | (485 K) | (485 K) | (485 K) | (485 K) | (485 K) | (485 K) | (485 K) | (485 K) | (485 K) | 191.3 K | 852 K | 478.6 K | 478.6 K | 550.3 K | 285.2 K |
| SOND | (178.2 M) | (178.2 M) | (178.2 M) | (178.2 M) | (178.2 M) | (178.2 M) | (178.2 M) | (178.2 M) | (178.2 M) | (178.2 M) | (250.3 M) | (294 M) | (245 M) | (295.7 M) | (295.7 M) | (224.1 M) | (235.3 M) |
| YYGH | 362.9 K | 362.9 K | 362.9 K | 362.9 K | 362.9 K | 362.9 K | 362.9 K | 362.9 K | 362.9 K | 362.9 K | 362.9 K | 362.9 K | 761.6 K | 852.3 K | (4.8 M) | (4.4 M) | (4.1 M) |
| DSS | (456.6 K) | (3.2 M) | (4.3 M) | 2.6 M | (41.2 M) | (14.3 M) | (950 K) | (578 K) | 1.5 M | (2.9 M) | 1.9 M | (33.1 M) | (59.8 M) | (60.6 M) | (46.9 M) | (42.2 M) | (40.1 M) |
| BTBD | 255.1 K | 255.1 K | 255.1 K | 255.1 K | 259.5 K | (254.9 K) | (254.9 K) | (254.9 K) | 20.8 K | (368.6 K) | 792 K | 607.9 K | (562.3 K) | (887.4 K) | (2.3 M) | (2.1 M) | (2 M) |
| ATER | (23.1 M) | (23.1 M) | (23.1 M) | (23.1 M) | (23.1 M) | (23.1 M) | (23.1 M) | (23.1 M) | (31.8 M) | (58.8 M) | (63.1 M) | (236 M) | (196.3 M) | (74.6 M) | (11.9 M) | (10.7 M) | (11.2 M) |
| LOBO | 569.5 K | 569.5 K | 569.5 K | 569.5 K | 569.5 K | 569.5 K | 569.5 K | 569.5 K | 569.5 K | 569.5 K | 569.5 K | 1.6 M | 1.1 M | 969.6 K | (812.8 K) | (731.6 K) | (695 K) |
| FLYE | 408 K | 408 K | 408 K | 408 K | 408 K | 408 K | 408 K | 408 K | 408 K | 408 K | 408 K | 408 K | 1.4 M | 1.9 M | (5.3 M) | (4.8 M) | (4.5 M) |
| FGI | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 4.7 M | 7.9 M | 3.7 M | 733.6 K | (1.2 M) | (1.1 M) | (1 M) |
| CENN | (21.1 M) | (21.1 M) | (21.1 M) | (21.1 M) | (21.1 M) | (19.1 M) | (10.8 M) | (5.8 M) | (33.8 M) | (19.5 M) | (5.2 M) | (16.4 M) | (110.1 M) | (54.2 M) | (44.9 M) | (40.4 M) | (42.4 M) |
Medirom Healthcare and related stocks such as Park Ha Biological, Sonder Holdings, and YY Group Holding Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Medirom Healthcare financial statement analysis. It represents the amount of money remaining after all of Medirom Healthcare Technologies operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Medirom Healthcare Technologies | MRM |
Specialization | Consumer Cyclical, Health Care Equipment & Services |
| Business Address | 2-3-1 Daiba, Tokyo, |
| Exchange | NASDAQ Exchange |
USD 1.36
Check out Medirom Healthcare Performance and Medirom Healthcare Correlation. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Medirom Healthcare technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.